Neogap and Cellerys enter collaboration related to Phase II study of a new therapy for multiple sclerosis
Neogap Therapeutics, a privately held biopharmaceutical company focusing on immuno-oncology based at the Centre for Molecular Medicine at Karolinska Institutet, Stockholm, Sweden, and Cellerys, a Zurich-based company researching an innovative therapy to fight multiple sclerosis (MS), have entered a collaboration.Cellerys will use Neogap’s patented EpiTCer[® ]technology in its upcoming Phase II study of a new type of cell therapy aimed at inducing antigen-specific immune tolerance in patients with multiple sclerosis (MS). Neogap EpiTCer[® ]technology will help detect rare autoreactive T